GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dynavax Technologies Corp (LTS:0IDA) » Definitions » Cyclically Adjusted Revenue per Share

Dynavax Technologies (LTS:0IDA) Cyclically Adjusted Revenue per Share : $1.33 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Dynavax Technologies Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Dynavax Technologies's adjusted revenue per share for the three months ended in Mar. 2024 was $0.390. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $1.33 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Dynavax Technologies's average Cyclically Adjusted Revenue Growth Rate was 13.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 37.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -2.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Dynavax Technologies was 37.70% per year. The lowest was -36.80% per year. And the median was -15.10% per year.

As of today (2024-06-09), Dynavax Technologies's current stock price is $12.20. Dynavax Technologies's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $1.33. Dynavax Technologies's Cyclically Adjusted PS Ratio of today is 9.17.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Dynavax Technologies was 37.42. The lowest was 1.18. And the median was 6.30.


Dynavax Technologies Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Dynavax Technologies's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dynavax Technologies Cyclically Adjusted Revenue per Share Chart

Dynavax Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.41 0.53 0.68 1.11 1.29

Dynavax Technologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.17 1.20 1.23 1.29 1.33

Competitive Comparison of Dynavax Technologies's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Dynavax Technologies's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dynavax Technologies's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dynavax Technologies's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Dynavax Technologies's Cyclically Adjusted PS Ratio falls into.



Dynavax Technologies Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Dynavax Technologies's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.39/131.7762*131.7762
=0.390

Current CPI (Mar. 2024) = 131.7762.

Dynavax Technologies Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.116 100.560 0.152
201409 0.084 100.428 0.110
201412 0.087 99.070 0.116
201503 0.023 99.621 0.030
201506 0.053 100.684 0.069
201509 0.033 100.392 0.043
201512 0.021 99.792 0.028
201603 0.024 100.470 0.031
201606 0.069 101.688 0.089
201609 0.004 101.861 0.005
201612 0.189 101.863 0.245
201703 0.004 102.862 0.005
201706 0.002 103.349 0.003
201709 0.001 104.136 0.001
201712 0.000 104.011 0.000
201803 0.003 105.290 0.004
201806 0.020 106.317 0.025
201809 0.023 106.507 0.028
201812 0.085 105.998 0.106
201903 0.091 107.251 0.112
201906 0.128 108.070 0.156
201909 0.141 108.329 0.172
201912 0.126 108.420 0.153
202003 0.127 108.902 0.154
202006 0.027 108.767 0.033
202009 0.120 109.815 0.144
202012 0.177 109.897 0.212
202103 0.734 111.754 0.866
202106 0.444 114.631 0.510
202109 0.926 115.734 1.054
202112 1.035 117.630 1.159
202203 0.763 121.301 0.829
202206 1.711 125.017 1.804
202209 1.107 125.227 1.165
202212 1.215 125.222 1.279
202303 0.367 127.348 0.380
202306 0.396 128.729 0.405
202309 0.451 129.860 0.458
202312 0.430 129.419 0.438
202403 0.390 131.776 0.390

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Dynavax Technologies  (LTS:0IDA) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Dynavax Technologies's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=12.20/1.33
=9.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Dynavax Technologies was 37.42. The lowest was 1.18. And the median was 6.30.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Dynavax Technologies Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Dynavax Technologies's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Dynavax Technologies (LTS:0IDA) Business Description

Industry
Traded in Other Exchanges
Address
2100 Powell Street, Suite 900, Emeryville, CA, USA, 94608
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Dynavax Technologies (LTS:0IDA) Headlines

No Headlines